Overview
Phase 1 to Evaluate the Safety and Pharmacokinetic Characteristics of Fixed-dose Combination of YYC506
Status:
Active, not recruiting
Active, not recruiting
Trial end date:
2021-07-31
2021-07-31
Target enrollment:
0
0
Participant gender:
Male
Male
Summary
To evaluate the safety and pharmacokinetics characteristics between YYC506 and concomitant administration of YYC506-T and YYC506-APhase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Yooyoung Pharmaceutical Co., Ltd.
Criteria
Inclusion Criteria:- Over 19 ages healthy men
- Over 50.0kg, 18.0kg/m2 ≤ BMI ≤ 30.0kg/m2
- Men who don't have congenital disease and other cronic disease need to be cared. etc.
Exclusion Criteria:
- Men who have congenital liver disease (AST, ALT, CK ≥ 2X ULN)
- Men who have drunken or eatten something including caffeine within 24 hours before.
etc.